CA3176523A1 - Compositions et methodes comprenant des dendrimeres et des agents therapeutiques - Google Patents

Compositions et methodes comprenant des dendrimeres et des agents therapeutiques Download PDF

Info

Publication number
CA3176523A1
CA3176523A1 CA3176523A CA3176523A CA3176523A1 CA 3176523 A1 CA3176523 A1 CA 3176523A1 CA 3176523 A CA3176523 A CA 3176523A CA 3176523 A CA3176523 A CA 3176523A CA 3176523 A1 CA3176523 A1 CA 3176523A1
Authority
CA
Canada
Prior art keywords
cancer
subject
composition
dendrimers
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3176523A
Other languages
English (en)
Inventor
Sujatha Kannan
Rana RAIS
Kannan Rangaramanujam
Anjali Sharma
Barbara Slusher
Carolyn TALLON
Ajit Thomas
Ranjeev Kumar PANDEY
Jonathan Powell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA3176523A1 publication Critical patent/CA3176523A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne le développement de compositions de dendrimères conjuguées à un ou plusieurs agents thérapeutiques qui réduisent la sécrétion d'exosomes et leurs procédés d'utilisation pour le traitement, l'atténuation et/ou la prévention d'un ou de plusieurs symptômes associés à une ou plusieurs maladies ou troubles neurologiques, le cancer, les maladies inflammatoires, les infections bactériennes et virales, et d'autres troubles. De préférence, les agents thérapeutiques sont un ou plusieurs agents qui inhibent ou réduisent l'activité et/ou la quantité de sphingomyélinase 2 neutre (nSMase2), tels que des inhibiteurs à petites molécules de nSMase2. Les compositions sont particulièrement appropriées pour réduire la formation de plaque A?, réduire la propagation de tau, améliorer la cognition, ou des combinaisons de celles-ci chez un sujet présentant des troubles psychiatriques et neurologiques. Les compositions sont également appropriées pour traiter, soulager et/ou prévenir un ou plusieurs symptômes associés au cancer, aux infections bactériennes et virales et aux maladies inflammatoires. L'invention concerne également des méthodes de traitement d'un sujet humain ayant une ou plusieurs maladies ou un ou plusieurs troubles.
CA3176523A 2020-04-24 2021-04-23 Compositions et methodes comprenant des dendrimeres et des agents therapeutiques Pending CA3176523A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063015118P 2020-04-24 2020-04-24
US63/015,118 2020-04-24
PCT/US2021/028971 WO2021217086A1 (fr) 2020-04-24 2021-04-23 Compositions et méthodes comprenant des dendrimères et des agents thérapeutiques

Publications (1)

Publication Number Publication Date
CA3176523A1 true CA3176523A1 (fr) 2021-10-28

Family

ID=75919413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3176523A Pending CA3176523A1 (fr) 2020-04-24 2021-04-23 Compositions et methodes comprenant des dendrimeres et des agents therapeutiques

Country Status (6)

Country Link
US (1) US20230218581A1 (fr)
EP (1) EP4138821A1 (fr)
JP (1) JP2023523238A (fr)
AU (1) AU2021259868A1 (fr)
CA (1) CA3176523A1 (fr)
WO (1) WO2021217086A1 (fr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10A (en) 1836-08-10 Gtttlslto andi
US6552A (en) 1849-06-26 Amos w
US4897388A (en) 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
IL110309A0 (en) 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
JP5484339B2 (ja) 2007-10-05 2014-05-07 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
WO2010147831A1 (fr) * 2009-06-15 2010-12-23 Wayne State University Nanodispositifs à base de dendrimère pour des objectifs thérapeutiques et d'imagerie
EP2552458A4 (fr) * 2010-03-31 2014-08-27 Univ Wayne State Nanoparticules d'hydrogel de dendrimère injectables
AU2015253100B2 (en) 2014-04-30 2018-01-18 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
EP3180032A1 (fr) 2014-08-13 2017-06-21 The Johns Hopkins University Compositions de dendrimères et utilisation dans le traitement de troubles neurologiques et du systeme nerveux central
CN115350285A (zh) 2014-08-13 2022-11-18 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
AU2018365250B2 (en) 2017-11-10 2022-05-26 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
US11766423B2 (en) 2018-03-01 2023-09-26 The Johns Hopkins University 2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a small molecule inhibitor of neutral sphingomyelinase 2 (nSMase-2) for the treatment of neurodegenerative and oncologic diseases

Also Published As

Publication number Publication date
JP2023523238A (ja) 2023-06-02
AU2021259868A1 (en) 2022-11-24
WO2021217086A1 (fr) 2021-10-28
EP4138821A1 (fr) 2023-03-01
US20230218581A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
US20210252153A1 (en) Selective dendrimer delivery to brain tumors
JP6531164B2 (ja) 神経障害およびｃｎｓ障害の処置におけるデンドリマー組成物および使用
Xie et al. Dual-sensitive nanomicelles enhancing systemic delivery of therapeutically active antibodies specifically into the brain
Xu et al. Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice
Yu et al. Recent advances in dendrimer research for cardiovascular diseases
JP2016104732A (ja) 薬物担体
CA2788736C (fr) Macromolecules multivalentes polyanioniques pour le ciblage intracellulaire de la proliferation et de la synthese de proteines
US20240058459A1 (en) Dendrimer compositions and methods for drug delivery to the eye
WO2014138186A1 (fr) Systèmes d'administration bi-composant bioorthogonal pour l'internalisation améliorée de produits nanothérapeutiques
WO2023122599A1 (fr) Dendrimères glycosylés pour une administration intracellulaire ciblée
JP2019510085A (ja) 癌治療のためのナノ粒子ならびに方法および化合物
CA3189682A1 (fr) Compositions de dendrimeres et procedes d'administration de medicament dans un rein malade
US20230218581A1 (en) Compositions and methods comprising dendrimers and therapeutic agents
WO2020218481A1 (fr) Méthode et composition pour administrer un fragment de liaison à l'antigène d'un anticorps au cerveau
WO2021230375A1 (fr) Peptide modifié par un polymère hydrophile non chargé modifié par un ligand glut1 dans un environnement réducteur ou un environnement à faible ph, et anticorps comprenant ledit peptide
EP4322961A1 (fr) Conjugués dendrimère-glutamine antagoniste et leurs procédés d'utilisation
WO2023196386A1 (fr) Compositions de dendrimères pour l'administration ciblée d'agents thérapeutiques à des neurones
JP2023540138A (ja) 肝細胞に標的化細胞内送達を行うためのガラクトシル化デンドリマー
WO2024020597A1 (fr) Administration de système crispr/cas intracellulaire ciblé activé par dendrimère et édition de gène
WO2024044760A1 (fr) Conjugués dendrimères d'agents antidépresseurs et antipsychotiques et leurs procédés d'utilisation
CA3166527A1 (fr) Compositions et methodes de traitement de troubles neurodegeneratifs, neurodeveloppementaux, myodegeneratifs et du stockage lysosomal

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230329

EEER Examination request

Effective date: 20230329